Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

79 results about "Early-stage cancer" patented technology

This stage is usually a small cancer or tumor that has not grown deeply into nearby tissues. It also has not spread to the lymph nodes or other parts of the body. It is often called early-stage cancer. Stage II and Stage III.

Computational pathology systems and methods for early-stage cancer prognosis

ActiveUS20170270666A1Reduce computing costInformed choiceImage enhancementImage analysisComputational pathologyLow risk group
The subject disclosure presents systems and computer-implemented methods for providing reliable risk stratification for early-stage cancer patients by predicting a recurrence risk of the patient and to categorize the patient into a high or low risk group. A series of slides depicting serial sections of cancerous tissue are automatically analyzed by a digital pathology system, a score for the sections is calculated, and a Cox proportional hazards regression model is used to stratify the patient into a low or high risk group. The Cox proportional hazards regression model may be used to determine a whole-slide scoring algorithm based on training data comprising survival data for a plurality of patients and their respective tissue sections. The coefficients may differ based on different types of image analysis operations applied to either whole-tumor regions or specified regions within a slide.
Owner:VENTANA MEDICAL SYST INC

Molecular lymphatic mapping of sentinel lymph nodes

The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye / radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and / or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.
Owner:JOHN WAYNE CANCER INST

Quantitative test to detect disease progression markers of epithelial ovarian cancer patients

InactiveUS20090123932A1Avoided technical biasMicrobiological testing/measurementOncologyDisease progression
The present invention concerns a method of prognosing the risk of early ovarian cancer relapse in a subject having ovarian cancer comprising: a) detecting the level of at least one marker selected from the group consisting of BTF4, GCS and HLA-DRbeta1; and b) comparing the level of the above at least one marker with that of a corresponding control sample, wherein the detection of a lower level of the at least one marker compared to that in the control sample is indicative that the subject is at risk of early cancer relapse. Also provided is a method of stratifying a subject suffering from ovarian cancer based on the expression levels of the disclosed markers and kits for practicing the methods of the present invention.
Owner:LE CENT HOSPITALER DE LUNIV DE MONTREAL

G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker

A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng / ml was developed.
Owner:TEMPLE UNIVERSITY

Detection Panel and kit for pan-cancerous detection or targeted medication based on second generation sequencing and application

The invention discloses a detection Panel and kit for pan-cancerous detection or targeted medication based on second generation sequencing and application of the detection Panel and kit. The detectionPanel comprises a target gene region used for detecting pan-cancerous mutation burden and mutation sites related to targeted medication, and an exon region related to pan-cancerous mutation sites. According to the invention, a liquid (blood) biopsy method is adopted, and a combined determination method is used for carrying out genetic change and protein biomarkers; the detection Panel not only can identify the existence of relatively early cancers, but also can locate origin organs of the cancers, has higher sensitivity, can better carry out combined detection, and provides more accurate support for treatment diagnosis of targeting drugs, chemotherapeutic drugs or immune drugs; and by designing and integrating common areas of different mutation-type information, the uniformity of the Panel is improved, the overall data volume of the Panel is reduced, and the cost is reduced.
Owner:合肥诺为尔基因科技服务有限公司

Multi-modal intelligent auxiliary diagnosis and treatment system for medical images

PendingCN112802000ASolve resource problemsSolve the problem of information storageImage enhancementImage analysisMedical recordImaging processing
The invention belongs to the technical field of medical treatment and relates to a multi-modal intelligent auxiliary diagnosis and treatment system formedical images. The system comprises an acquisition unit and a diagnosis and treatment information management unit; the diagnosis and treatment information management unit is provided with an analysis unit and a diagnosis and treatment unit; the acquisition unit acquires a plurality of comparative cases; image processing and category analysis are carried out on the comparative cases through a processing comprehensive unit; the comparative cases are sent to an analysis unit; after biological characteristics of the comparative cases are analyzed through an optimization unit; the analysis unit carries out AI prognosis algorithm detection on the comparative cases through an algorithm unit; the acquisition unit acquires diagnosis and treatment data and medical record information of a patient through a diagnosis and treatment instrument; an image preprocessing unit preprocesses the diagnosis and treatment data and sends the data to the diagnosis and treatment unit; a comparison unit compares detection data of the algorithm unit; and the score and the diagnosis report of a radiation prediction carrier are obtained through a detection unit. The problems of low film reading efficiency of a hospital and failure of the hospital to pre-judge early-stage cancers are solved.
Owner:上海集迈医疗科技有限公司

A method for detecting, screening and/or monitoring a cancer in an individual

InactiveCN1685235ASimple and cheap detection methodSimple and cheap monitoring methodDisease diagnosisBiological testingMedicineCancer treatment
The present invention relates to methods for screening and / or detecting and / or monitoring cancer in an individual. The method includes determining a first parameter represented by the concentration of TIMP-1 in at least one excreta from the individual, such as saliva. The present invention provides a method that can easily diagnose early-stage cancer, monitor the recurrence of cancer, and / or monitor the status of cancer or the effect of cancer treatment in an individual without using blood samples.
Owner:里格舒斯匹塔里特医院 +1

Combined general check protein chip for early-stage cancers mainly comprising lung cancer

The invention discloses a combined general check protein chip for early-stage cancers mainly comprising lung cancer and belongs to the technical field of a protein chip. The combined general check protein chip for the early-stage cancers mainly comprising the lung cancer, provided by the invention, comprises a chip substrate and marker antibodies distributed on the chip substrate, wherein the chip substrate is an FAST protein chip substrate having a three-dimensional nitrocellulose basic material; one or more sample application module is arranged on the FAST protein chip substrate; the following marker antibodies are fixed on the sample application module: 14-3-3 theta, LAMR-1, TSGF (Tumor Specific Growth Factor), CEA (Cancer Embryo Antigen), SCC (Squamous Cell Carcinoma), CYFRA21-1 and positive control; the following marker antibodies are also fixed: AFP (Alpha Fetal Protein), CA242, MG-Ag, CA199, TPA (Tissue Polypeptide Antigen) and EA-IgA; and the following marker antibodies are further fixed: CA125, CA153, SF (Serum Ferritin) and PSA (Prostate Specific Antigen). According to the combined general check protein chip provided by the invention, the related indexes are highly integrated; the combined general check protein chip has the advantages of excellent stability, strong specificity, long retention period, high sensitivity, excellent repeatability, convenience in operation and low cost; the labor efficiency is increased; and a cancer patient is diagnosed and treated from the general check before clinical symptoms occur.
Owner:马鞍山微因泰克生物科技有限公司

Suspicious early-stage cancer lesion examination device suitable for endoscopy

ActiveCN103169446AIdentify the site of cancerClear scopeEndoscopesDiseaseColposcopes
The invention discloses a suspicious early-stage cancer lesion examination device suitable for an endoscopy. A medical endoscope (a gastroscope, an enteroscope, a bronchoscope, a cystoscope, a colposcope, a laparoscope and the like) used in medical clinical examinations becomes an important tool for disease diagnosis. Many cancers can be found through observing the morphological characteristic of a pathological changed region, however, the pathological changes of early-stage cancers without remarkable morphological characteristics are difficultly detected, a great number of medical researches show that the early-stage pathological changes of the cancers are not remarkably changed in shape, but fluorescent substances in the cancer tissue are changed along with the formation of the canceration, then, the fluorescence of a cancer tissue is caused to be greatly different from that of a normal tissue, and thus, the suspicious lesions of the early-stage cancers are identified easily through fluorescence detection and expression of a difference by using a false color image way, the pathological biopsy can also be precisely indicated, and the suspicious early-stage cancer lesion examination device plays an important role in increasing the detection rate and the accuracy rate of early-stage cancer diagnosis.
Owner:叶衍铭

Ultraspecific nucleic acid sensors for low-cost liquid biopsies

Ultraspecific, programmable nucleic acid sensors capable of detecting and preferentially amplifying target DNA molecules comprising a particular SNP or mutation are provided. In some cases, the ultraspecific programmable nucleic acid sensors are useful for detecting SNP-containing DNA molecules indicative of cancer such as cell-free DNA circulating in the blood or indicative of organ transplant rejection Also provided are methods for construction of such ultraspecific nucleic acid sensors and methods for preferential amplification of target DNA molecules containing a mutation of interest, as well as testing systems for early cancer screening and routine monitoring of circulating cancer DNA using liquid biological samples such as serum, plasma, or saliva.
Owner:ARIZONA STATE UNIVERSITY

SERS labeled nanoprobe with gold-hexanethiol-mesoporous silicon structure, and preparation method and application thereof

The invention discloses an SERS labeled nanoprobe with a gold-hexanethiol-mesoporous silicon structure, and a preparation method and application thereof. According to the preparation method, introducing hexanethiol and mesoporous silicon into the surfaces of gold nanoparticles marked by 4-MBA to form an SERS marked nanoprobe with a gold-hexanethiol-mesoporous silicon structure, and fixing signal molecules by utilizing molecular intervals formed by hexanethiol so as to weaken thermotactic motion of the signal molecules under laser thermal induction, so that a more stable Raman signal is formed;the coated mesoporous silicon forming a structure similar to a molecular sieve, so that the influence of biomacromolecules in cells on signal molecules is avoided, and the stability and accuracy of Raman signals are further improved. The nanoprobe disclosed by the invention can be massively prepared in advance. During operation, only the nanoprobe needs to be introduced into cancer cells for co-mixed culture, and detection can be immediately carried out by washing after completion: the collection time is 1s, and then the pH value is read out from a standard curve, so that rapid quantitative detection is realized. The nanoprobe can be applied to clinical diagnosis and screening of early-stage cancers.
Owner:SOUTH CHINA NORMAL UNIVERSITY

Receptor-modified and receptor-free titanium dioxide nano metal film Raman chips and manufacturing method

The invention discloses receptor-modified and receptor-free titanium dioxide nano metal film Raman chips and a manufacturing method. Each chip is composed of a surface enhanced Raman scattering (SERS) film and a carrier thereof, the carriers comprise the capillary type carrier, the small box type carrier and the microfluidic channel type carrier, the SERS-films comprise the receptor-modified SERS-film and the receptor-free SERS-film, and six types of the Raman chips are obtained. Control standards are set in the manufacturing method, and the controllable SERS-film manufacturing method comprises the steps that 1, a titanium dioxide film is pulled through a sol-gel method, and scattered particles are crystallized; 2, a second-layer nano silver foil/silver particle SERS-film grows through photocatalysis; 3, the second-layer SERS-film is modified with specifically coordinated and combined receptor molecules through hydrogen bonding force or immune bonding force according to the needs of detected object donor molecules, and then a third-layer SERS-film is formed. The Raman chips can be applied to environmental pollution treatment and detection, hard drug and warfare agent detection, pesticide residue detection, harmful food additive screening, large-scale early-stage cancer Raman screening and the like.
Owner:大连世佩达光谱智能检测科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products